PRINCETON, N.J., March 31, 2023--BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...
PRINCETON, N.J., March 30, 2023--Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung...